Generate Biomedicines vs Nabla Bio (2026)
Both generate protein therapeutics with machine learning rather than discovering them, and they differ in reach and stage. Generate Biomedicines designs proteins of many kinds with its Chroma model, which it published in Nature and released as open source, and runs a continuous generate, build, measure and learn loop across more than forty thousand proteins. It is clinical stage, with programs in Phase 1 trials and a large discovery deal with Novartis. Nabla Bio is narrower by design: antibodies against the membrane protein class, with results published target by target and the misses stated. It is preclinical, and its evidence is the detail of its reporting and its three pharmaceutical collaborations. Generate is the one for a broad generative protein platform with molecules already in the clinic. Nabla is the one for a membrane target where a focused antibody design engine and published hit rates are what a program needs.
- A broad generative protein platform built on Chroma, published in Nature and released open source.
- Clinical stage programs in Phase 1 trials and a large discovery collaboration with Novartis.
- A generate, build, measure and learn loop reported across more than forty thousand proteins.
- Antibody design concentrated on multipass membrane proteins rather than proteins broadly.
- Hit rates published target by target, including the targets that produced nothing.
- Collaborations with three large pharmaceutical companies against the platform.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Generate Biomedicines and Nabla Bio are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Generate Biomedicines | Nabla Bio |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2018 | 2021 |
| Headquarters | Somerville, MA | Cambridge, Massachusetts, United States |
| Website | generatebiomedicines.com | nabla.bio |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Generate Biomedicines its top capability grade on AI Centrality and Clinical and Operational Evidence. Set against Nabla Bio, Generate Biomedicines grades higher on Clinical and Operational Evidence, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Its thinnest published disclosure sits on Security Certifications and Trust Center and EHR and Interoperability Depth. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, October 2026
The AI Health Index awards Nabla Bio its top capability grade on AI Centrality and AI Governance and Bias Disclosure. Set against Generate Biomedicines, Nabla Bio grades higher on AI Governance and Bias Disclosure and AI Liability and Recourse. Its thinnest published disclosure sits on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, October 2026
Questions buyers ask
Should we choose Generate Biomedicines or Nabla Bio?
On the axes where the AI Health Index separates them, Generate Biomedicines grades higher on Clinical and Operational Evidence, AI Safety and PHI Stewardship and HIPAA and BAA Posture, and Nabla Bio grades higher on AI Governance and Bias Disclosure and AI Liability and Recourse. Generate Biomedicines leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Generate Biomedicines and Nabla Bio differ most?
The widest separation the AI Health Index records between Generate Biomedicines and Nabla Bio is on AI Governance and Bias Disclosure, where Generate Biomedicines grades C and Nabla Bio grades A. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Generate Biomedicines and Nabla Bio grade the same?
The AI Health Index grades Generate Biomedicines and Nabla Bio the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Generate Biomedicines and Nabla Bio not disclosed?
At the last review, at least one of Generate Biomedicines and Nabla Bio published thin or absent detail on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both records were reviewed in October 2026. Neither publishes a price; both earn through partnerships, with Generate also carrying its own clinical pipeline.
Ask both how their published results map to a target like yours, and what each commits to when a designed protein fails to perform.